FDA
-
-
-
-
-
-
-
Harrow Announces Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
-
-
-
-
-
-
-
Harrow Health (HROW) to Launch FDA-Approved IHEEZO at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
-
-
-
-
-
-
-
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
-
-
-
-
-
-
-
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
-
-
-
-
-
-
-
Harrow and iOR Partners Expand National Product Supply Agreement
-
-
-
-
-
-
-
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
-
251,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All